Oregovomab: Anti-CA-125 monoclonal antibody B43.13 - AltaRex, B43.13, MAb B43.13, monoclonal antibody B43.13

Drugs in R and D

Volumn 7, Issue 6, 2006, Pages 379-383

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; DOXORUBICIN; MONOCLONAL ANTIBODY; OREGOVOMAB; PACLITAXEL; PLACEBO; TOPOTECAN;

CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DENDRITIC CELL; DRUG INDUSTRY; DRUG MECHANISM; GEOGRAPHIC DISTRIBUTION; HUMAN; OVARY CANCER; PRIORITY JOURNAL; REVIEW; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIBODIES, MONOCLONAL; CA-125 ANTIGEN; CLINICAL TRIALS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MICE; OVARIAN NEOPLASMS; TREATMENT OUTCOME;

EID: 33750575656     PISSN: 11745886     EISSN: 11745886     Source Type: Journal    
DOI: 10.2165/00126839-200607060-00007     Document Type: Review

References (20)

1. AltaRex Corporation. Extension of License Agreement to United Therapeutics Corporation. Media Release: 11 Aug 2003. Available from URL: http://www.altarex.com
2. AltaRex. AltaRex Signs Distribution Agreement with Dompe. Media Release: 6 Jul 2004. Available from URL: http://www.altarex.com
3. United Therapeutics Corporation. OvaRex Phase III Trials Are Fully Enrolled. Media Release: 20 Jun 2006. Available from URL: http://www.unither.com
4. ViRexx Medical Corp. ViRexx Announces Enrollment Completion of Ovarex'R' MAb Phase III Trial for Ovarian Cancer. Media Release: 14 Dec 2005. Available from URL: http://www.virexx.com
5. United Therapeutics Corporation. Unither Pharmaceuticals Completes Enrollment in First of Two Phase III Trials of OvaRex in Advanced Ovarian Cancer. Media Release: 12 Dec 2005. Available from URL: http://www.unither.com
6. ViRexx Medical Corp. ViRexx Announces 2005 Fiscal Year Results. Media Release: 16 Mar 2006. Available from URL: http://www.virexx.com
7. AltaRex Corp. AltaRex Receives OvaRex(R) Orphan Drug Designation in Europe. Media Release: 2 Aug 2002. Available from URL: http://www.altarex.com
8. AltaRex Corp. AltaRex reports OvaRex(R) primary analysis results from placebo-controlled trial. Media Release [3 pages], 27 Jul 2001. Available from URL: http://www.altarex.com
9. Fingert H, Nicodemus C, Siemens M, et al. Clinical development of Ovarex MAb-B43.13 monoclonal antibody for treatment of ovarian cancer: impact of immune responses and circulating CA 125 levels on clinical efficacy. European Journal of Cancer 37 (Suppl. 6): 260 (plus poster), Oct 2001
10. AltaRex Corporation. AltaRex Updates OvaRex(R) Clinical Program at EORTC Meeting in Frankfurt. Media Release: 22 Nov 2002. Available from URL: http://www.altarex.com
11. Schultes BC, Yang R, Agopsowicz K. Anti-idiotype induction therapy for ovarian cancer: immune status of patients injected with OvaRex (TM) and its correlation with survival. Cancer Vaccine Week 1998: DO1, 5 Oct 1998
12. Baum R, Niesen A, Korz W, et al. Treatment of ovarian cancer patients with MAb-B43.13 (OvaRex) and the role of positron emission tomography imaging. Gynecologic Oncology 76: 279-280, Feb 2000
13. Ehlen T, Whiteside T, Schultes B, et al. Induction of tumor protective immunity utilizing the CA125 specific monoclonal, OvaRex MAb-B43-13, in a cohort of patients with advanced recurrent ovarian cancer. Gynecologic Oncology 80: 310, Feb 2001
14. AltaRex Corp. AltaRex reports favorable OvaRex (Rm) phase II trial results. Media Release [3 pages], 3 Jan 2001. Available from: URL: http://www.altarex.com
15. Ehlen T, Nicodemus C, Hoskins P, et al. Immunization of advanced ovarian cancer patients with MAb-B43.13 (Ovarex Tm). Blood 94 (Suppl. 1): 52, Part 2, 15 Nov 1999
16. Bolle M, Niesen A, Korz W, et al. Possible role of anti-CA125 monoclonal antibody B43.13 (OvaRex TM) administration in long term survival of relapsed ovarian cancer patients. 36th Annual Meeting of the American Society of Clinical Oncology 19: 476 (plus poster), 20 May 2000
17. AltaRex Corp. AltaRex reports positive OvaRex (R) long-term survival and safety results. Media Release [2 pages], 12 Jul 2001. Available from URL: http://www.altarex.com
18. AltaRex Corp. AltaRex announces positive OvaRex (Rm) chemotherapy trial results at SGO. Media Release: 18 Mar 2002. Available from URL: http://www.altarex.com
19. AltaRex Corp. AltaRex Phase II OvaRex(R) Survival Data Presented at Society for Gynecological Oncology. Media Release: 3 Feb 2003. Available from URL: http://www.altarex.com
20. Ehlen TG, Gordon AN, Fingert HJ, et al. Adjuvant treatment with monoclonal antibody, OvaRex MAb-B43.13 targeting CA125, induces robust immune responses associated with prolonged time to relapse in a randomized, placebo-controlled study in patients with advanced epithelial ovarian cancer. 38th Annual Meeting of the American Society of Clinical Oncology 21: 9 (plus poster), Part 1, 18 May 2002